During the five months from December 2019 to April 2020, the Covid-19 virus has infected more than 1.5 million people and caused almost 92,000 deaths.
Despite aggressive global physical distancing efforts, experts say we won’t see the end of this pandemic until someone develops a vaccine.
Enter Dartmouth, Nova Scotia-based medtech firm, IMV Inc. This biopharmaceutical company has been researching ways to activate the human immune system to overcome complex and devastating diseases such as ovarian, lung, liver, bladder, melanoma and other cancers. Now they are turning their attention to Covid-19.
In an interview with Atlantic Business Magazine editor Dawn Chafe, IMV’s VP of Research and Development — Dr. Marianne Stanford — says her firm’s previous work on respiratory illnesses led them to believe they had a role to play in fighting Covid-19.
IMV hopes to initiate Phase 1 clinical trials of their DPX-Covid-19 vaccine in summer 2020.